SR Pharma to acquire Atugen

SR Pharma (LSE:SPA) will acquire Atugen (Berlin, Germany) in a stock deal that values Atugen at about L6.2 million ($11.3 million), based on a price of 27p per share of SPA. Shareholders of Atugen, which is developing RNAi therapeutics for cancer, will own a maximum of 49% of the combined company after the deal, which the companies expect to complete by July 12. ...